Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA bonuses rise

Executive Summary

FDA bonuses exceeding $4,000 increased by an estimated $8 million in 2007 over 2006 figures, according to data released by the House Energy and Commerce Committee. The agency's highest-paid officials received many of the retention bonuses, which totaled $35 million last year. "These back-scratching bonuses could be used to hire inspectors that might have gone to China and uncovered the unsafe manufacturing practices that led to the heparin deaths," said Committee Chair John Dingell, D-Mich. Such outcries, which also followed the announcement of FDA bonus figures last year, are drawing more scrutiny as the agency calls for additional funds to keep pace with scientific advancements (1"The Pink Sheet," July 23, 2007, In Brief)

You may also be interested in...



FDA brass paid to stay

FDA employees received $9.5 million in retention bonuses last year, leaving Congress asking why as much was spent on retention as on increased food safety oversight. At a July 17 House Energy and Commerce Committee Subcommittee on Oversight and Investigations hearing, Rep. Bart Stupak, D-Mich., also notes that employees in the commissioner's office "collected more than 30 percent of all the top FDA cash awards in 2004, 2005 and 2006; and the Office of Regulatory Affairs only received 19 percent of all FDA's top cash awards, yet has 35 percent of all FDA employees"...

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.

Global Pharma Guidance Tracker – March 2020

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

UsernamePublicRestriction

Register

PS049812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel